Telix Bets $1.65B on Radiopharma Rival to Take On Novartis
- Telix Pharmaceuticals agreed to acquire Germany's ITM for $1.65 billion upfront, plus up to $700 million in milestones tied to its lead radiopharmaceutical candidate.
- The deal pairs Telix's diagnostics business with ITM's lutetium-177 supply chain, setting up direct competition with Novartis' Lutathera in neuroendocrine cancer.
- Telix will assume some of ITM's debt, and the companies expect to close the transaction by year-end 2026.
💡 Points
At $1.65B upfront plus $700M in milestones — and assumed debt pushing the all-in cost near $2.4B — Telix is essentially replicating Novartis's own AAA/Endocyte playbook: buy the isotope supply chain, not just the molecule. Pairing ITM's Lu-177 manufacturing with Telix's diagnostics scale is the only realistic way a challenger dents Lutathera's neuroendocrine near-monopoly.
Telix beams into Novartis' territory with $1.6B ITM acquisition ↗